afucosylated monoclonal antibodies

Afucosylated monoclonal antibodies overcome this problem through improved FcγIIIa binding.

The use of afucosylated monoclonal antibodies in therapy was pioneered by two major pharma companies - Kyowa Hakko Kirin and Roche.

Afucosylated monoclonal antibodies are monoclonal antibodies engineered so that the oligosaccharides in the Fc region of the antibody do not have any fucose sugar units.

Roche manufactures afucosylated monoclonal antibodies in CHO cells lines, where the cell has been engineered to overexpress an enzyme called GnTIII.

Kyowa Kirin Hakko manufactures afucosylated monoclonal antibodies in CHO cells in which the endogenous FUT8 gene has been knocked out.